On
A refrigerated truck loaded with Saint Relais slowly drove out of the production base. Going nationwide marks that Saint Relais is about to be officially put into clinical use, bringing new hope for efficient and high-quality treatment to the vast number of patients with renal anemia.
'Once a month, you can reach the standard with peace of mind.' Hansoh Pharmaceutical Saint Relais is the world's only highly specific small peptide agonist of EPO receptors. It has potential safety advantages and only needs to be administered once every 4 weeks, greatly reducing the frequency of administration and helping to significantly improve patient treatment.
Saint Relais was approved for marketing in June this year and is suitable for the treatment of anemia caused by chronic kidney disease (CKD), including adult non-dialysis patients who are not receiving erythropoiesis stimulating agents (ESA), and those who are receiving short-acting erythropoiesis-stimulating agents. Adult dialysis patients treated with EPO. Saint Relais has filled the gap in the new generation of
Following the successful launch of
Strive for excellence and achieve perfection.
About CKD renal anemia
Renal anemia is one of the most common complications of CKD. Epidemiological data show that the prevalence of CKD among Chinese adults is 10.8%, and more than 50% of them are anemic [1] and with the progression of CKD, the prevalence of renal anemia continues to increase, and the overall anemia rate among non-dialysis CKD patients is The prevalence rate is 28.5%-72.0%, while the prevalence rate of anemia among dialysis patients is as high as 91.6%-98.2%[2]. The latest data shows that as of the end of 2022, the number of dialysis patients in my country (including
About Saint Relais
Saint Relais (Pemosatide Injection) is 'the world's only highly specific small peptide agonist for EPO receptors' independently developed by
Contact:
Tel: 0518-83096666
Email: PV.SERVICE@hspharm.com
(C) 2023 Electronic News Publishing, source